Pediatric urology : Wilms tumour

469 views 80 slides Jun 02, 2021
Slide 1
Slide 1 of 80
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67
Slide 68
68
Slide 69
69
Slide 70
70
Slide 71
71
Slide 72
72
Slide 73
73
Slide 74
74
Slide 75
75
Slide 76
76
Slide 77
77
Slide 78
78
Slide 79
79
Slide 80
80

About This Presentation

Wilms tumour


Slide Content

DE PT O F URO L O GY
GO VT RO YAPE T T AH HO S PI T AL AND K I L PAUK M E DI C AL C O L L E G E
C HE NNAI

WILMS TUMOUR

1

Moderators:
Professors:
Prof. Dr. G. Sivasankar, M.S., M.Ch.,
Prof. Dr. A. Senthilvel, M.S., M.Ch.,

Asst Professors:
Dr. J. Sivabalan, M.S., M.Ch.,
Dr. R. Bhargavi, M.S., M.Ch.,
Dr. S. Raju, M.S., M.Ch.,
Dr. K. Muthurathinam, M.S., M.Ch.,
Dr. D. Tamilselvan, M.S., M.Ch.,
Dr. K. Senthilkumar, M.S., M.Ch.
Dept of Urology, GRH and KMC, Chennai.
2

INTRODUCTION
Nephroblastoma

most common primary malignant renal tumour of
childhood

embryonal tumour that develops from remnants of
immature kidney


.



3
Dept of Urology, GRH and KMC, Chennai.

EPIDEMIOLOGY
6% to 7% - all childhood cancers.

95% of all kidney cancers in children under age of 15

 AI : 7-10/ million

> 80% of patients are diagnosed before 5 years of age,
with a median age of 3.5 years.

The median age at diagnosis is lower in children with
bilateral Wilms tumour (Breslow et al, 1993).



4
Dept of Urology, GRH and KMC, Chennai.

frequency in females > males

Several epidemiologic studies have investigated
occupational, environmental, and lifestyle factors
as risk factors for Wilms

Incidence lower in Asian population & higher in
black populations compared with North American
& European whites.


5
Dept of Urology, GRH and KMC, Chennai.

BIOLOGY AND GENETICS
Majority of Wilms tumours arise from somatic
mutations restricted to tumour tissue and a much smaller
percentage originate from germline mutations.

10% of children with Wilms tumour have congenital
anomalies and syndromes

5% to 10% of tumours are bilateral and multicentric

1% to 2% are familial



6
Dept of Urology, GRH and KMC, Chennai.

CONGENITAL ANOMALY A/W wilms TUMOUR

1.Cryptorchidism
2.Duplex renal collecting system
3.Horse shoe kidney
4.hypospadias

7
Dept of Urology, GRH and KMC, Chennai.

8
Dept of Urology, GRH and KMC, Chennai.

WT 1
The first gene mutation described (both somatic and
germline mutations )

gross deletions at chromosome 11p13

WT1 encodes a zinc finger transcription regulating
mesenchymal to epithelial transition in kidney
development.

WT1 is necessary for ureteric bud outgrowth,
nephrogenesis & normal gonadal development


9
Dept of Urology, GRH and KMC, Chennai.

associated with beta-catenin (CTNNB1) mutations,
defining a specific genetic subset of Wilms tumour
called the ideal type 1 Wilms tumour

stromal-predominant, favorable histology,
intralobar nephrogenic rests (ILNRs)

early onset of Wilms tumour, and genitourinary
abnormalities in males.
10
Dept of Urology, GRH and KMC, Chennai.

Associated Syndromes
1.WAGR syndrome
2.Denys-Drass Syndrome
3.Frasier Syndrome



11
Dept of Urology, GRH and KMC, Chennai.

WAGR syndrome
oWilms tumour
oAniridia
ogenital anomalies
omental retardation

Aniridia, found in 1.1% of Wilms tumour patients & caused by an
abnormality of the PAX6 gene located adjacent to the WT1 gene

Wilms tumour will develop in 40% to 70% of aniridia patients
with deletions of WT1.

WAGR patients and those with genitourinary abnormalities have
an increased risk of renal failure if they survive into puberty

12
Dept of Urology, GRH and KMC, Chennai.

DDS
1. Male pseudohermaphroditism,
2. renal mesangial sclerosis,
3. nephroblastoma

caused by point mutations in the zinc finger DNA binding
region of WT1 (Coppes et al, 1993).

> 90% of DDS patients harbor germline point mutations in
only one WT1 allele, Therefore the WT1 mutation acts
dominantly with respect to genitourinary abnormalities


13
Dept of Urology, GRH and KMC, Chennai.

Denys-Drash mutations do not result in inactivation of
the WT1 protein, but rather in the production of a
dysfunctional WT1 protein

The majority of these patients progress to end-stage
renal disease.

Nephropathy usually manifests early in life, and renal
biopsy demonstrates mesangial sclerosis.

Some WT1 mutations can lead to an incomplete DDS
phenotype, with varying degrees of genitourinary
anomalies, renal pathologies, and penetrance of Wilms
tumour
14
Dept of Urology, GRH and KMC, Chennai.

WAGR and DDS patients have bilateral tumours and are
diagnosed at a younger age


The incidence of WT1 mutations in patients with wilms
tumour not associated with any genitourinary
abnormality is approximately 2%
15
Dept of Urology, GRH and KMC, Chennai.

 FRASIER SYNDROME

1.WILMS Tumour (5%)
2.Gonadoblastoma (50%)
3.Male pseudohermaphroditism
4.Nephropathy ( FSGS-LATER)
16
Dept of Urology, GRH and KMC, Chennai.

WTX

 tumour suppressor gene targeted by somatic mutations -
30%

role in the Wnt/beta-catenin signaling pathway

Most have deletions of the entire WTX gene, but 1/3
carry truncating mutations or missense mutations

Location Xq11.1

17
Dept of Urology, GRH and KMC, Chennai.

 it is inactivated by a monoallelic or “single-hit”
event rather than by the classical biallelic
inactivation of autosomal tumour suppressor
genes.

It targets the single X chromosome in males and
the active X chromosome in females with tumours


18
Dept of Urology, GRH and KMC, Chennai.

WT 2


LOH or loss of imprinting (LOI) on 11p15 occurs in 70%

Gene involved H19 & IGF-2

Wilms tumour associated with epigenetic alterations in
the 11p15 region has been termed the ideal type 2 Wilms
tumour

A type 2 Wilms tumour is characterized by limited
nephrogenic differentiation and blastemal or epithelial-
type histology


19
Dept of Urology, GRH and KMC, Chennai.

develop tumours at later age and have heavier birth
weight.

21% - bilateral disease at presentation

A/W Beckwith-Wiedemann syndrome (BWS) and other
syndromes with overgrowth features including
hemihypertrophy, which may occur alone or as part of
BWS or Perlman, Soto, and Simpson-Golabi-Behmel
syndromes


20
Dept of Urology, GRH and KMC, Chennai.

BWS

Excess growth at cellular, organ ( macroglossia,
nephromegaly,hepatomegaly) or body segment
( hemihypertrophy ) level

Most cases are sporadic, 15% heritable – AD

The risk of nephroblastoma - 4% to 10%;
21
Dept of Urology, GRH and KMC, Chennai.

Adrenocortical neoplasms and hepatoblastoma
occur with increased frequency

increased Wilms tumour risk - ICR1 gain of
methylation and 11p15 uniparental disomy.

In contrast, the tumour risk is lower - ICR2 loss of
methylation and CDKN1C mutations.

22
Dept of Urology, GRH and KMC, Chennai.

FAMILIAL WILMS tumour
1% to 2% of Wilms tumour

earlier age of onset and an increased frequency of
bilateral disease.

Two familial Wilms tumour genes have been localized
(Ruteshouser and Huff, 2004).
FWT1 is located at 17q12-q21
FWT2 at 19q13.4
23
Dept of Urology, GRH and KMC, Chennai.

Other Chromosomal Abnormalities




TP53 mutations - 75% of Wilms tumour with AHWT

favorable-histology tumour may progress to an anaplastic
tumour by acquiring a disruption of TP53 function.

The TP53 mutations correlated with advanced-stage disease

Loss 16q - 20%

loss of 1p - 10%

Both A/w increased risk of tumour relapse and death

24
Dept of Urology, GRH and KMC, Chennai.

SCREENING

Screening recommended when WT incidence > 5 %

Infants younger than 12 months found to have NRs in the
resected kidney are at the greatest risk for metachronous
tumours.

USG surveillance is performed at time of diagnosis until 5
years of age, with a frequency of every 3 to 4 months

BWS, Simpson-Golabi-Behmel syndrome, and familial Wilms
continue to 7 years


Early detection can provide an opportunity for NSS because
these children are at an increased risk for bilateral disease. But
not improved survival.
25
Dept of Urology, GRH and KMC, Chennai.

Screening of the contralateral kidney after nephrectomy
for unilateral Wilms tumour

CT or MRI should be performed if ultrasonography
demonstrates a suspicious lesion

An association between Wilms tumour and horseshoe
kidney has been noted ….7 X also in MCDK

risk of müllerian duct anomalies in girls - 10% of girls
such as duplication of the cervix or uterus or bicornuate
uterus.


26
Dept of Urology, GRH and KMC, Chennai.

27
Dept of Urology, GRH and KMC, Chennai.

PATHOLOGY

Favorable-Histology Wilms tumour (90%)

compresses adjacent normal renal parenchyma, forming a
intrarenal pseudocapsule composed of compressed atrophic
renal tissues.

The texture of the tumours varies depending on the
predominant histologic pattern.

 Many are soft and friable with necrotic or hemorrhagic areas
frequently noted which increases the risk of intraoperative
tumour rupture during primary nephrectomy

28
Dept of Urology, GRH and KMC, Chennai.

Extrarenal Wilms tumour - displaced metanephric
elements or mesonephric remnants

tremendous histologic diversity, often contains tissues such
as skeletal muscle, cartilage, and squamous epithelium.

“Classic” Wilms tumour
1.islands of compact undifferentiated Blastema
2.presence of variable Epithelial differentiation in the
form of embryonic tubules, rosettes, and glomeruloid
structures
3.separated by a significant STromal component
29
Dept of Urology, GRH and KMC, Chennai.

Wilms tumours with predominantly epithelial differentiation
have a low degree of aggressiveness and the majority are
stage I tumours

more resistance to therapy, If they are present at advanced
stage disease

30
Dept of Urology, GRH and KMC, Chennai.

31
Dept of Urology, GRH and KMC, Chennai.

SURVICAL RATE IN FAVORABLE HISTOLOGY

STAGE RELAPSE FREE
SURVIVAL
OS
1 92 98
2 85 96
2 90 95
4 80 90
32
Dept of Urology, GRH and KMC, Chennai.

ANAPLASTIC WILMS tumour


Anaplasia is characterized by presence of 3 abnormalities
1.nuclear enlargement to three or more times the diameter of
the adjacent cells
2.hyperchromasia of enlarged nuclei
3. abnormal mitotic figure.

rarely seen in children < 2 years (incidence about 2% )

resistance to chemotherapy.

poor prognosis even when the tumour is apparently confined
to the kidney, stage I

33
Dept of Urology, GRH and KMC, Chennai.

PATHOLOGY AFTER PREOPERATIVE CHEMOTHERAPY


Stroma and Epithelial predominant tumours are found more
often after chemotherapy

poor clinical response to therapy but have an excellent
prognosis if the tumour is completely excised

The proportion of blastemal-predominant tumours is
decreased after chemotherapy, have a high rate of relapse
34
Dept of Urology, GRH and KMC, Chennai.

SIOP classifies tumours with complete tumour necrosis after
preoperative chemotherapy as “low-risk.”

Children with stage I low risk tumours after post-
chemotherapy nephrectomy receive no further chemotherapy

Tumours with diffuse anaplasia and blastemal predominance
after chemotherapy are classified as “high-risk”

SIOP “intermediate-risk” tumours consist of all other
histologies.

35
Dept of Urology, GRH and KMC, Chennai.

NEPHROGENIC RESTS

Precurson lesions ; most do not form wilms tumour.

A rest can undergo maturation, sclerosis, involution, or
complete disappearance.

NRs can be separated into two fundamentally distinct
categories,
1. perilobar nephrogenic rests (PLNRs)
2. intralobar nephrogenic rests (ILNRs)
36
Dept of Urology, GRH and KMC, Chennai.

PLNRs
1.found only in the lobar periphery
2.elaborated late in embryogenesis
3.Subcortical
4.sharply demarcated
5.predominantly blastema & tubules
6.found in children with BWS, linked to 11p15

37
Dept of Urology, GRH and KMC, Chennai.

ILNRs
1.anywhere within the lobe, as well as renal sinus
and the wall of PCS
2.result of earlier gestational aberrations
3.stroma rich and intermingle with the adjacent
renal parenchyma.
4.seen in children with aniridia, WAGR, and DDS
or other features associated with WT1

38
Dept of Urology, GRH and KMC, Chennai.

Multiple rests in one kidney usually implies that NRs are
present in the other kidney

Hyperplastic NRs can produce a renal mass that can be
mistaken for a small Wilms tumour (Beckwith, 1998)
.
Wilms tumour will have a spheric shape, whereas
hyperplastic rests will retain the appearance of the original
rest and be more elliptical or lenticular in shape

Nephroblastomatosis refers to the presence of multiple NRs.

Diffuse overgrowth of PLNRs may produce a thick rind that
enlarges the kidney but preserves its original shape

39
Dept of Urology, GRH and KMC, Chennai.

40
Dept of Urology, GRH and KMC, Chennai.

PREOPERATIVE EVALUATION AND
STAGING


> 90% asymptomatic smooth abdominal mass discovered
incidentally by a family member or physician

The mass may be extremely large relative to the size of child

20% - hematuria

25% - hypertension d/t elevated plasma renin; resolves after
nephrectomy

fever, anorexia, and weight loss in 10% of patients.

41
Dept of Urology, GRH and KMC, Chennai.

ACUTE abdomen from tumour rupture into the
peritoneal cavity or bleeding within the tumour

42
Dept of Urology, GRH and KMC, Chennai.

Extension into IVC & renal vein (10%) - A persistent
varicocele in the supine position, hepatomegaly d/t hepatic
vein obstruction, ascites

Atrial thrombus may manifest as HTN / CHF

Acquired WVD – 8 % newly diagnosed

Physical examination reveals firm, nontender mass that
classically does not cross the midline.



43
Dept of Urology, GRH and KMC, Chennai.

blood count, liver enzymes, and serum electrolytes, including
blood urea nitrogen, creatinine, and calcium

 Coagulation profile

This defect can be corrected preoperatively with the
administration of 1-desamino-8-D-arginine-vasopressin
(DDAVP)
44
Dept of Urology, GRH and KMC, Chennai.

IMAGING

All of the solid renal tumours of childhood have some common
radiographic features including renal cell carcinoma (RCC)

 important role - confirm that the contralateral kidney is
functioning before performing a nephrectomy

CHEST RADIOGRAPHY – may show lung metastasis

ULTRASONOGRAPHY
o1 st study to evaluate children with an abdominal mass
owill demonstrate the solid nature of the lesion.
oDoppler ultrasonography is helpful to exclude intracaval tumour
extension that occurs in 4% of Wilms tumour.

45
Dept of Urology, GRH and KMC, Chennai.

All patients should undergo either CECT OR MRI of the
abdomen and pelvis with gadolinium

CT SCAN
origin of the tumour
SIZE
C/L kidney involvement
LN involvement
invasion into major vessels
liver metastasis

46
Dept of Urology, GRH and KMC, Chennai.

has moderate specificity but poor sensitivity in the detection
of preoperative tumour rupture
Ascites beyond the cul-de-sac was most strongly associated
with tumour rupture

CT CHEST to rule out lung metastasis

MRI abdomen
ocan reliably identify extension of tumour into the IVC
oT1 –low signal intensity
oT2 - high signal intensity

47
Dept of Urology, GRH and KMC, Chennai.

48
Dept of Urology, GRH and KMC, Chennai.

PROGNOSTIC FACTORS





•Most important determinant of outcome – Histopathology
and tumour stage

•Clinical trials are now incorporating biological factors that
predict tumour behaviour

•LOH for a portion of chromosome 16q and/or 1p has been
noted in 20% of Wilms tumours. This is associated with an
increased risk for relapse

•High telemerase activity – unfavourable prognostic feature




49
Dept of Urology, GRH and KMC, Chennai.

DNA content : Aneuploidy & DNS index 1.5 strongly a/w
anaplastic histology

lung metastases were far more likely to occur in animals
with VEGF-positive tumours.

 Anti-VEGF therapy has been shown to suppress tumour
growth in mice and can prevent development of metastases.

Antiangiogenesis treatment would appear to be a promising
adjunctive future treatment for patients with Wilms
tumour.
50
Dept of Urology, GRH and KMC, Chennai.

Treatment


Usual approach – Nephrectomy followed by chemotherapy
with or without postoperative radiotherapy

Multiple RCT to determine therapeutic protocol by :
1.NWTSG / COG
2.SIOP
3.UKCCSG
51
Dept of Urology, GRH and KMC, Chennai.

52
Dept of Urology, GRH and KMC, Chennai.

COG PROTOCOL FOR HIGH RISK
Focal anaplastic stage stage 1-3
Diffuse anaplastic stage 1
Nephrectomy
Vincristine, Dactinomycin, Doxo
+ local RT
Focal Anaplastic stage 4
Diffuse anaplastic stage 2-3



Diffuse anaplastic stage 4
SAME
+ Cyclo, Eto, Carbo



More aggressive t/t
Nephrectomy
Irinitacan & Vincristine
Dactinomycin, doxo,cyclo, carbo, eto,
RT
53
Dept of Urology, GRH and KMC, Chennai.

Surgical Considerations

Radical Nephrectomy via transperitoneal approach.

Thorough exploration of the abdominal cavity to exclude
local tumour extension, liver and nodal metastases, and
peritoneal seeding.

Accurate staging to determine appropriate chemotherapy &
need for radiation therapy.

Formal RPLND is not recommended but selective sampling
of suspicious nodes is essential.

54
Dept of Urology, GRH and KMC, Chennai.

Exploration of the contralateral kidney is no longer
mandatory if preoperative CT or MRI demonstrates a normal
kidney

The renal vein and IVC are palpated to exclude intravascular
tumour extension before vessel ligation.

The adrenal gland can be spared without increasing the risk
for tumour spill or recurrence if it is not in close proximity to
the tumour (Kieran et al, 2013a)

Extensive lymph node dissection, particularly above the renal
hilum, can result in chylous ascites
55
Dept of Urology, GRH and KMC, Chennai.

major responsibility - complete removal of the tumour
without contamination of the operative field.

A recent COG study reported intraoperative tumour
spillage in 9.7% of patients undergoing primary nephrectomy
…….. common with right-sided tumours and larger tumours.

risk factors for local tumour recurrence
1.tumour spillage
2.unfavorable histology
3.incomplete tumour removal
4.absence of any lymph node sampling
56
Dept of Urology, GRH and KMC, Chennai.

This study included both stage II and III disease. The risk of
recurrence was highest in patients with stage II disease.

 recent COG studies treated all spill patients - stage III
disease.

laparoscopic nephrectomy - done in conjunction with
preoperative chemotherapy and is likely more feasible after
the tumour is reduced in size (Duarte et al, 2009).

 open nephrectomy after chemotherapy - less prone to
tumour spillage.
57
Dept of Urology, GRH and KMC, Chennai.

Preoperative chemotherapy may influence surgical
complication rates by producing tumour shrinkage.

A recent report from the UKCCSG - significantly fewer
complications in those undergoing delayed nephrectomy (1%
vs. 5.8%). Performed after 6 weeks of CT.

58
Dept of Urology, GRH and KMC, Chennai.

PREOPERATIVE CHEMOTHERAPY
(Children’s Oncology Group Recommendations)

COG protocols - treatment is dependent on surgical and
pathologic staging after immediate nephrectomy.

preoperative chemotherapy is recommendation
1.children for whom RSS is planned
2.tumours inoperable at surgical exploration
3.tumour extension into the IVC above the hepatic veins.
59
Dept of Urology, GRH and KMC, Chennai.

Inoperablility should not be based on preoperative imaging
studies, which can overestimate local tumour extension.

IF unresectable - pretreatment with chemotherapy almost
always reduces the bulk of tumour and renders it resectable

inoperable tumour should be considered stage III disease
and should be treated accordingly

Experience in SIOP shown - majority of reduction (48%)
in tumour volume occurs in the first 4 weeks of therapy but
that reduction extends out through 8 weeks.

60
Dept of Urology, GRH and KMC, Chennai.

SIOP
61
Dept of Urology, GRH and KMC, Chennai.

Repeat imaging is performed after 6 weeks of chemotherapy.

After adequate shrinkage of the tumour, definitive resection can
be completed.

A clinically good response (by imaging) is usually associated
with a pathologically good response in terms of regressive
histologic changes

The distribution of histologic subtypes is different after
preoperative chemotherapy compared with primary surgery,
with differentiation of the tumour occurring after CT.

62
Dept of Urology, GRH and KMC, Chennai.

Stromal- and epithelial predominant tumours are
found more often after treatment with preoperative
chemotherapy.

These histologic subtypes may demonstrate a poor
clinical response to therapy but have an excellent
prognosis if the tumour is completely excised.

Failure to achieve a reduction in volume is the result of
tumour differentiation

63
Dept of Urology, GRH and KMC, Chennai.

64
Dept of Urology, GRH and KMC, Chennai.

BILATERAL WILMS tumourS


Synchronous bilateral Wilms tumours - 5% to 7%

 no initial radical nephrectomy.

preoperative CT for 6 weeks - current COG protocol

tumour response is assessed after 6 weeks with CT or MRI to
determine the reduction in tumour volume and feasibility of
RSS

•tumours not responding to therapy require bilateral open
biopsy to determine histology & additional chemo based on
biopsy findings


65
Dept of Urology, GRH and KMC, Chennai.

•bilateral biopsies are recommend because anaplasia is found
to be discordant between the two kidneys in 83% of children

•proceed to surgical resection within 12 weeks of starting
therapy ( no benefit beyond 12 weeks )

•Even when large bilateral masses remain after initial
chemotherapy, a high percentage of children can be
successfully managed with RSS ( partial nephrectomy, wedge
resection)

•The kidney with the lower tumour burden is addressed first.


66
Dept of Urology, GRH and KMC, Chennai.

It is easy to underestimate the amount of renal
parenchyma that can be salvaged as a result of
compression by the tumour therefore NSS should be
considered in all patients




67
Dept of Urology, GRH and KMC, Chennai.

68
Dept of Urology, GRH and KMC, Chennai.

tumour enucleation may be considered in lieu of a
formal partial nephrectomy - for large centrally located
tumours when removal of a margin of renal tissue
would compromise the vascular supply to the kidney

enucleation more likely to result in positive surgical
margins.
-favorable-histology tumours - adjuvant therapy may
still achieve a good outcome
-Anaplasia - positive margin will adversely affect
survival and requires additional resection

69
Dept of Urology, GRH and KMC, Chennai.

•Radical nephrectomy may be needed in a kidney with
extensive tumour involvement.

•Bilateral nephrectomies and dialysis are rarely required
when the tumours fail to respond to CT / RT

•anephric patients can still be administered chemotherapy
with some modifications

•renal transplant - 2 years to ensure that the patient does
not develop metastatic disease



70
Dept of Urology, GRH and KMC, Chennai.

renal failure after RSS - removal of the remaining renal tissue
before transplant to prevent tumour recurrence after starting
immunosuppression

Need long term follow up ( SIOP - late relapse - more than 4
years after treatment )

These patients should also have frequent assessment of renal
function, urine protein, and blood pressure

71
Dept of Urology, GRH and KMC, Chennai.

PARTIAL NEPHRECTOMY FOR UNILATERAL tumourS


 the incidence of renal failure after nephrectomy
0.6% at 20 years

The risk of renal failure is higher for patients with
genitourinary anomalies, DDS, and WAGR.

Syndromic patients likely have smaller tumours &
more amenable to renal-sparing surgery

Most Wilms tumours are too large at diagnosis to
allow partial nephrectomy.

72
Dept of Urology, GRH and KMC, Chennai.

 After preoperative chemotherapy, partial nephrectomy can
be performed in 10% to 15% of patients.

Patients who develop intra-abdominal relapse have a
markedly decreased survival

The COG is conducting a renal-sparing protocol for select
patients with unilateral Wilms tumours known to be at risk
for bilateral disease or at increased risk for renal failure.
73
Dept of Urology, GRH and KMC, Chennai.

The lesion should be completely excised with a margin of
normal renal parenchyma.

patients should not undergo partial nephrectomy if the
tumour cannot be removed at stage I.

 Patients with high-risk histologic patterns such as anaplasia
or persistent blastemal-predominant tumour after
chemotherapy should be treated with complete nephrectomy
because these tumours have resistance to chemotherapy
74
Dept of Urology, GRH and KMC, Chennai.

LATE EFFECTS OF TREATMENT

Fertility and Pregnancy

Gonadal radiation - hypogonadism and temp.
azoospermia

severity of damage - dose dependent.

Leydig cells are more radioresistant but higher doses can
result in inadequate production of testosterone….result
in delayed sexual maturation

Chemotherapeutic agents adversely affect testicular
function

75
Dept of Urology, GRH and KMC, Chennai.

Pelvic irradiation and exposure to alkylating agents -
ovarian failure and premature menopause

offspring of irradiated female - risk for LBW &
premature birth.

 Radiation risk miscarriage

Musculosceletal problem like scoliosis
76
Dept of Urology, GRH and KMC, Chennai.

Second Malignancies

1% cumulative incidence at 10 years post-diagnosis

greatest risk factors is prior irradiation, and most
tumours occur in the radiation field

The incidence of leukemia is highest during the first 5
years after Wilms tumour treatment.

The incidence of solid tumours increases fivefold from
age 15 to 40 years

77
Dept of Urology, GRH and KMC, Chennai.

Cardiac Effects

CHF- 4.4% among DOX-treated patients who received
this drug as part of their initial chemotherapy regimen
(Green et al, 2001b).

The risk was increased if the patient received whole-lung
or left-flank irradiation.

78
Dept of Urology, GRH and KMC, Chennai.

79 Dept of Urology, GRH and KMC, Chennai.

Thank you
80
Dept of Urology, GRH and KMC, Chennai.